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Abstract 
Background: Artemisinin-based combination therapy has been first-line treatment for falciparum malaria in Myan-
mar since 2005. The wide extent of artemisinin resistance in the Greater Mekong sub-region and the presence of 
mefloquine resistance at the Myanmar-Thailand border raise concerns over resistance patterns in Myanmar. The avail-
ability of molecular markers for resistance to both drugs enables assessment even in remote malaria-endemic areas.
Methods: A total of 250 dried blood spot samples collected from patients with Plasmodium falciparum malarial 
infection in five malaria-endemic areas across Myanmar were analysed for kelch 13 sequence (k13) and pfmdr1 copy 
number variation. K13 mutations in the region corresponding to amino acids 210–726 (including the propeller region 
of the protein) were detected by nested PCR amplification and sequencing, and pfmdr1 copy number variation by 
real-time PCR. In two sites, a sub-set of patients were prospectively followed up for assessment of day-3 parasite clear-
ance rates after a standard course of artemether-lumefantrine.
Results: K13 mutations and pfmdr1 amplification were successfully analysed in 206 and 218 samples, respectively. 
Sixty-nine isolates (33.5 %) had mutations within the k13 propeller region with 53 of these (76.8 %) having mutations 
already known to be associated with artemisinin resistance. F446I (32 isolates) and P574L (15 isolates) were the most 
common examples. K13 mutation was less common in sites in western border regions (29 of 155 isolates) compared 
to samples from the east and north (40 of 51 isolates; p < 0.0001). The overall proportion of parasites with multiple 
pfmdr1 copies (greater than 1.5) was 5.5 %. Seven samples showed both k13 mutation and multiple copies of pfmdr1. 
Only one of 36 patients followed up after artemether-lumefantrine treatment still had parasites at day 3; molecular 
analysis indicated wild-type k13 and single copy pfmdr1.
Conclusion: The proportion of P. falciparum isolates with mutations in the propeller region of k13 indicates that 
artemisinin resistance extends across much of Myanmar. There is a low prevalence of parasites with multiple pfmdr1 
copies across the country. The efficacy of artemisinin-based combination therapy containing mefloquine and lume-
fantrine is, therefore, expected to be high, although regular monitoring of efficacy will be important.
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Background
The morbidity and mortality of falciparum malaria have 
reduced remarkably in many malaria-endemic areas 
following the expanding use of insecticide-treated bed 
nets and artemisinin-based combination therapy (ACT) 
[1], although more than half a million deaths still occur 
annually [2]. The emergence of resistance to ACT in 
Cambodia [3, 4] and Thailand [5, 6] threatens to under-
mine further reductions in malaria mortality, and track-
ing the extent of anti-malarial resistance is urgent given 
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the consequences of the previous global spread of chloro-
quine and sulfadoxine-pyrimethamine resistance.
Myanmar is likely to become a critical site for con-
trolling malaria parasites and malaria remains one of 
its diseases of national concern. In 2013, malarial mor-
bidity and mortality rates were 6.44/1000 population 
and 0.48/100,000 population, respectively, a consid-
erable decrease in disease burden when compared to 
1990, when morbidity and mortality were 24.4/1000 
and 12.6/100,000, respectively. Three ACT formulations 
(artemether-lumefantrine, artesunate-mefloquine and 
dihydroartemisinin-piperaquine) have been deployed as 
first-line treatment for acute uncomplicated Plasmodium 
falciparum malaria since 2005, with artemether-lume-
fantrine generally used in Ministry of Health facilities 
and dihydroartemisinin (DHA)-piperaquine used in 
military facilities. However, artemisinin monotherapy 
remains in use in the private sector [7]. There is currently 
no evidence of unsatisfactory efficacy of any of these 
ACT within Myanmar, although few therapeutic efficacy 
studies have been undertaken [8, 9]. Reduced in  vivo 
responses to artemisinins have been confirmed in the 
southern extremity of Myanmar [10] and at the Myan-
mar-Thai [5, 6, 11] and Myanmar-China borders [12].
The primary underlying molecular factors in resistance 
to several anti-malarials are known, allowing molecular 
surveillance of resistance in remote or logistically chal-
lenging environments where in vivo and in vitro studies 
are impractical. Artemisinin resistance is determined 
by mutation in the propeller region of the P. falciparum 
kelch protein gene on chromosome 13 (k13) [13–15] 
while mefloquine and lumefantrine resistance results 
from increased pfmdr1 copy number [16].
The main objective of the current study was to track 
the likely efficacy of artemether-lumefantrine and other 
ACT in several regions in Myanmar using the k13 and 
pfmdr1 copy number molecular markers.
Methods
Screening of patients and sample collection
Dried blood spot samples were collected from patients 
with microscopically confirmed P. falciparum infection 
during a one-year period from October 2013 to Sep-
tember 2014 in five malaria-endemic areas. The studied 
sites were Ann in Rakhine State, Homemalin in Saga-
ing State, Myit Kyi Nar in Kachin State, Kyauk Me in 
Northern Shan State, and Phruso in Kayah State. Accu-
rate and recent P. falciparum transmission data are not 
available from these sites, although up to 2010 the three 
administrative regions spanning the western Myanmar 
border (Rakhine and Chin States and Sagaing Region) 
appeared to have the highest transmission levels in the 
country (generally PfPR2-10 >5 to <40 %, or ‘intermedi-
ate levels’) with lower prevalence in central and eastern 
areas [17].
Febrile patients in the respective study sites were 
recruited by passive case sampling at local clinics run 
by the Vector Borne Disease Control Programme and 
by active case sampling at nearby villages. Positive rapid 
diagnostic test (RDT) results for falciparum malaria 
were confirmed by thick and thin blood film examina-
tion. Patients with parasite counts of 250 parasites/µl or 
more in the thick blood film were eligible for the study. 
After obtaining written informed consent, dried blood 
spot samples from participants were collected on What-
man 3MM filter paper (Maidstone, UK). The short-term 
efficacy of artemether-lumefantrine therapy via assess-
ment of day-3 parasitaemia (after completion of directly 
observed treatment) in a sub-set of patients studied in 
Homemalin and Kyauk Me were also done. The study was 
approved by the Ethical Committees of Faculty of Tropi-
cal Medicine, Mahidol University and Department of 
Medical Research (lower Myanmar).
Detection of k13 mutation
K13 sequences corresponding to amino acids 210–726 
were obtained; results from an initial set of 74 samples 
were published as a part of a previous study [18] (Addi-
tional file 1). Nested PCR methods were as described pre-
viously [14]. Briefly, each PCR reaction contained 10 mM 
Tris-HCL buffer, 2 mM or 3 mM MgCl2, 250 µM 4-deox-
ynucleotide triphosphate (dNTPs), 250  nM oligonu-
cleotide primers, 0.5 units (2 units for the second nested 
PCR) Platinum Taq DNA polymerase (Invitrogen, USA) 
and 2 µL of genomic DNA template (or 5 µL of PCR prod-
uct from the first nested PCR) within a final reaction vol-
ume of 100 µL. A total of 25 PCR cycles for nested 1 and 
35 cycles for nested 2 were undertaken using a MyCycler ™ thermal cycler (Bio-Rad Laboratories, USA). The tem-
perature cycles consisted of pre-denaturation at 94 °C for 
5 min followed by 94 °C for 1 min, 58 °C for 2 min (1 min 
for the second nested PCR), 72  °C for 2 min (1 min for 
nested 2) and final extension at 72  °C for 10 min. DNA 
template from the AQ strain (without k13 mutation) was 
used as a positive control and a DNA free template was 
also included as negative control in each PCR reaction. 
Sequencing of k13 was obtained at Macrogen, Repub-
lic of Korea. Multiple nucleotide sequence alignments 
were analysed by BioEdit version 7.1.3.0, using 3D7 k13 
sequence as a reference to detect point mutations in the 
gene. PCR and sequencing reactions were repeated when 
amplification did not occur or when the relevant por-
tion of the sequencing chromatogram was unclear at any 
point.
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Analysis of pfmdr1 copy number variation
Copy number variation in the pfmdr1 gene was assessed 
using a 5-plex Rotor Gene Q (Qiagen, Valencia, USA). 
The real-time PCR method was described previously 
[16, 19]. Briefly, each 10 µL PCR reaction contained 5 µL 
of 2x QuantiTect Multiplex PCR NoROX Master Mix 
(containing HotStarTaq DNA Polymerase and Quanti-
Tect Multiplex PCR Buffer), 0.4  µM of each forward 
and reverse primer for both the pfmdr1 gene and the Pf 
β-tubulin gene, 0.2 µM of each probe, and 2.5 µL of tem-
plate DNA. In each run of real-time PCR, 3D7 and H26 
clones were used as calibration controls with single and 
multiple copies of pfmdr1 gene, respectively, and negative 
control containing no template DNA was also included. 
Test samples were assayed in triplicate. The tempera-
ture profiles for real-time PCR were pre-denaturation at 
95 °C for 15 min followed by 45 cycles of 94 °C for 60 s 
and 60  °C for 60 s. Fluorescence data were expressed as 
normalized reporter signal. The detection threshold was 
set above the baseline value for fluorescence of the first 
15 cycles. The threshold cycle (Ct) is when the increase 
in reporter signal first rises above this threshold. Results 
were analysed by a comparative ∆∆Ct method where 
∆∆Ct = (Ct of Pfmdr1 gene−Ct of P fβ-tubulin) of sam-
ple- (Ct of Pfmdr1 gene−Ct of Pf β-tubulin) of Pf 3D7 
calibrator. The pfmdr1 copy number was calculated as 
2∆∆Ct. Samples with copy number between 1.45 and 1.6, 
and samples with a spread of ∆∆Ct among the three 
triplicates of more than 1 were repeated and the second 
result used.
Statistical analysis
Qualitative variables were presented as proportions 
with confidence intervals calculated by Wilson’s method 
and comparison of proportions undertaken by the Chi 
squared test. Quantitative variables were expressed as 
median (IQR).
Results
A total of 250 samples (76 from Ann, 111 form Homema-
lin, 38 from Myit Kyi Nar, 18 from Kyauk Me and seven 
from Phruso) were obtained for molecular analysis of 
K13 mutation and pfmdr1 copy number variation (Addi-
tional file 1). Median parasitaemia was 9047 parasite/µl. 
K13 sequencing and pfmdr1 copy number assessment 
were both successful in 176 samples; samples in which 
either or both markers could not be reliably assessed 
were spread across the five sites.
K13 sequence
K13 sequence was successfully obtained in 206 samples. 
Seventy-six samples (36.9 %) had non-synonymous muta-
tions (19 different mutations, of which six are previously 
unreported) (Table 1). There was no sample with multiple 
k13 mutations. Sixty-nine samples had non-synonymous 
mutations in the propeller region; 53 (76.8  %) of these 
had one of the mutations associated with artemisinin 
resistance according to the WHO definition of arte-
misinin resistance [20]: these were P441L, F446I, G449A, 
P574L, R561H, and A675 V.
The overall prevalence of k13 propeller mutations, and 
the most common mutation in each site differed among 
sites (Table  1; Fig.  1). Propeller mutation was less com-
mon in samples from sites in western border regions 
(Ann and Homemalin, 29 of 155 isolates) compared 
to samples from the other three sites (40 of 51 isolates; 
p  <  0.0001). F446I was the most common mutation in 
Myit Kyi Nar and Homemalin while P574L was most 
common in Kyauk Me.
Five different non-synonymous mutations in the non-
propeller (‘stem’) region of k13 (corresponding to amino 
acids 210–440) were found in Homemalin or Myit Kyi 
Nar; three of these were previously unreported. Two 
infections with previously unreported synonymous 
mutations (one with E424E in Ann and one with D343D 
in Homemalin) were also detected.
pfmdr1 copy number variation
A total of 218 samples were successfully analysed for 
copy number variation in the pfmdr1 gene. Using a copy 
number threshold of 1.5 to define multiple copies, only 
12/218 (5.5  %) of samples had multiple copies (Table  2; 
Fig.  1). The overall median copy number across all five 
study sites was 1.03 (IQR  =  0.86–1.2). The maximum 
copy number was 2.87 (in Homemalin). The proportion 
of samples having multiple copies was highest in Kyauk 
Me (four out of 13 samples). Only seven of 176 samples 
(4.0 %) with data for both genes had both k13 propeller 
mutations and multiple copies of pfmdr1.
Day‑3 parasitaemia after artemether‑lumefantrine therapy
Blood films from 36 patients (26 in Homemalin and ten 
in Kyauk Me) taken on day 3 following completion of a 
directly observed regimen of artemether-lumefantrine 
therapy were obtained. Only one patient from Homema-
lin had a positive blood film at this time (parasite count: 
50 parasites/µl). Molecular testing showed wild-type k13 
and single copy pfmdr1. Among the other 35 samples 
with negative day-3 parasitaemia, 19 were wild-type k13, 
nine had propeller mutations, two had non-propeller 
mutations and five could not be sequenced.
Discussion
K13 assessment
This study adds to the knowledge of anti-malarial resist-
ance in Myanmar. Approximately one-third of isolates 
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had k13 propeller mutations, with around three-quarters 
of these being mutations known to be associated with 
artemisinin resistance. Of the five locations surveyed, 
only Ann in Rhakhine State had a k13 propeller muta-
tion proportion of less than 10 %. This finding is consist-
ent with previous clinical and molecular data indicating 
that artemisinin resistance was not present in western 
Myanmar [9, 21], or in neighbouring Bangladesh [22]; 
the data also fit with lower levels of transmission (broadly 
found in the sites outside the western border regions) 
being associated with the most resistant parasites [23]. 
The high rate of mutation in Myit Kyi Nar (Kachin State) 
is consistent with data from neighbouring provinces of 
China where the F446I mutation is also the predominant 
type of k13 mutation and associated with slow parasite 
clearance [12, 24] and reduced in vitro susceptibility [24]. 
F446I was also the most common mutation in Homema-
lin, near the northwest border with India, where it was 
found in 13 of 91 isolates (14.3 %). The P574L mutation 
was also present in three sites, consistent with its iden-
tification in seven provinces [18, 25]; it has been shown 
to be associated with a relatively long parasite clearance 
half-life [25].
Most k13 mutations previously associated with slow 
parasite clearance (in Cambodia, Thailand and Vietnam) 
were not found in this study. This may reflect different 
levels of drug pressure and different population histories 
among study sites, although it is not possible to relate 
the mutations observed in different locations in Myan-
mar with particular drug usage histories, since these are 
largely unknown. The study also documents the presence 
at low frequency of a number of mutations in the ‘stem’ 
Table 1 Numbers of  non-synonymous mutations in  Plasmodium falciparum K13 gene corresponding to  amino acids 
210–726 in different sites in Myanmar
* Newly identified mutations from this study
** Includes single samples with previously unreported synonymous mutations in Ann (E424E) and Homemalin (D343D)
Ann Homemalin Myit Kyi Nar Kyauk Me Phruso Total
Total n 64 91 32 13 6 206
Wild type 61** 59** 6 0 4 126
Non-propeller mutations
 R254L* 1 1
 R255K 2 2
 E294G* 1 1
 I352T 2 2
 R411K* 1 1
 Total 0 6 1 0 0 7
 % 0 6.6 3.2 0 0 3.4
 (95 % CI) (0.0–5.7) (3.0–13.6) (0.56–15.8) (0–22.8) (0–39.0) (1.7–6.8)
Propeller mutations
 P441L 1 1
 P443S 3 3
 F446I 13 18 1 32
 G449A 1 1 2
 S485N 1 1
 Y511H* 1 1
 A529T* 1 1
 N554L* 1 1
 P574L 1 2 12 15
 R561H 1 1
 R575K 1 1
 A675V 2 2
 A676D 4 3 7
 H719N 1 1
 Total 3 26 25 13 2 69
 % 4.7 28.6 78.1 100 33.3 33.5
 (95 % CI) (1.6–12.9) (20.3–38.6) (61.2–89.0) (77.2–100) (9.7–70.0) (27.4–40.2)
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region of the k13 protein outside the propeller region. 
Although clearly less common than propeller muta-
tions, mutations in this highly conserved region may 
have functional consequences [26]. Further studies of k13 
mutation in conjunction with parasite clearance assess-
ment or in  vitro studies [27] should help to determine 
the relationship between this expanding list of observed 
mutations and phenotypic artemisinin resistance.
pfmdr1 copy number variation
In Southeast Asia and in laboratory studies, amplifica-
tion of the pfmdr1 gene has been shown to be associated 
with decreased in  vitro sensitivity to both mefloquine 
and lumefantrine [16, 28] and it is associated with meflo-
quine-artesunate failure in Cambodia [29, 30], presuma-
bly in concert with propeller mutations in k13 (present in 
high proportions in Cambodia for more than a decade). 
Recrudescences after the six-dose artemether-lumefan-
trine regimen have not been firmly linked with pfmdr1 
amplification [30], although relatively few artemether-
lumefantrine efficacy data are available from areas with 
artemisinin resistance.
Prior to this study, few surveys had been undertaken 
examining copy number variation in the pfmdr1 gene 
in Myanmar [31], although considerable data have been 
obtained from areas along the Thai-Myanmar [5, 32, 33] 
and China-Myanmar border areas [34, 35]. These studies 
have generally shown a prevalence of multiple copies of 
pfmdr1 gene of less than 10 %. In the current study the 
overall median copy number was 1.03 (IQR = 0.86–1.2) 
and the proportion of samples with multiple copy num-
bers (more than 1.5) was less than 10  % in three out of 
five studied sites (Ann, Homemalin and Myit Kyi Nar).
This generally low rate of isolates with multiple pfmdr1 
copies across the country reflects the fact that although 
ACT, artesunate-mefloquine and artemether-lumefan-
trine, have been policy for treatment of P. falciparum 
malaria since 2005, it has been challenging to deploy 
them particularly in remote regions. Parasites carrying 
multiple copies of pfmdr1 also have lower fitness in the 
absence of drug pressure [36]. The higher rates of multi-
ple copies found in eastern areas (Kyauk Me and Phruso) 
may reflect the relatively small sample numbers (13 and 
six from Kyauk Me and Phruso, respectively). Neverthe-
less, the findings raise the suspicion of possible mefloqine 
resistance in these sites, perhaps related to population 
migration in and out of areas where relevant ACT are 
used. Molecular studies with larger sample size com-
bined with clinical efficacy studies are needed to deter-
mine more accurately the drug resistance profile in these 
areas.
Day‑3 parasitaemia after artemether‑lumefantrine therapy
Among 36 patients assessed in Homemalin and Kyauk Me 
for day-3 parasitaemia after completion of artemether-
lumefantrine therapy, all patients cleared parasite on day 
Fig. 1 The prevalence of mutations in the propeller region of Plasmo-
dium falciparum k13 gene and Pfmdr1 amplification in different sites 
in Myanmar
Table 2 pfmdr1 copy number results by site
Single Multiple % multiple (95 % CI)
Ann 63 2 3.1 (0.8–10.6)
Homemalin 94 4 4.1 (1.6–10.0)
Myit Kyi Nar 35 1 2.8 (0.5–14.2)
Kyauk Me 9 4 30.8 (12.7–57.6)
Phruso 5 1 16.7 (3.0–56.4)
Total 206 12 5.5 (3.2–9.4)
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3 except one from Homemalin. This is quite surprising 
given the overall proportion of isolates with k13 propel-
ler mutations in these regions (28.6 % in Homemalin and 
100 % in Kyauk Me), and the day-3 positivity rate appears 
lower than the previous clinical study done in Shwe Kyin 
in Lower Myanmar (9 %) [14]. Different starting parasi-
taemias might explain this discrepancy (minimum count 
was only 250 parasite/µl in the current study and median 
parasitaemia was consequently substantially lower). 
Another possibility is that the quantitative aspects of the 
relationship between k13 propeller mutation and day-3 
positivity may differ according to the specific k13 muta-
tion. Independent studies at the Myanmar-China border 
indicate that the proportion of day 3-positive patients 
after artemisinin derivatives is around 5–20  % but the 
proportion of isolates with k13 propeller mutations 
(mostly F446I) was around 40–60 % [12, 24]. This differs 
from the situation in the lower Mekong region where the 
proportion of day 3-positive patients broadly matches 
that of k13 propeller mutants [14]. Hence, certain muta-
tions might have relatively mild phenotypes compared 
to better-characterized k13 mutants, such as C580Y. A 
number of host variables (including immunity, pharma-
cology and genetics) might also be contributing factors. 
Further, the relatively small number of patients assessed 
for day-3 parasitaemia limits the precision of the estimate 
of parasite clearance time for artemether-lumefantrine 
therapy.
Conclusions
This work describes two molecular markers of anti-
malarial resistance, k13 sequence and pfmdr1 copy num-
ber, and hence enhances knowledge of the distribution 
of drug-resistant falciparum malaria in five regions of 
Myanmar. K13 mutations are widespread, although with 
lower prevalence in western border regions. Pfmdr1 copy 
number is generally single. The ACT currently used in 
Myanmar, including DHA-piperaquine [37], are likely to 
be efficacious at present, although regular monitoring 
through therapeutic efficacy studies will be important if 
development of widespread resistance to ACT is to be 
prevented.
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